MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer

Liu, Di; Song, Lingqin; Dai, Zhijun; Guan, Huaijin; Kang, Huafeng; Zhang, Yinbin; Yan, Wanjun; Zhao, Xiaoyao; Zhang, Shuqun

doi:10.1016/j.bbrc.2018.09.147

Cited by 25 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDAC cells conditioned medium (CM) treatment significantly increased the neurite outgrowth percentage in PC-12 cells, which was suppressed by culturing with CM from miR-429 mimics-transfected cells. In the CM cultured PC-12 cells, NT-3 receptor TrkC as well as pain-related proteins TRPV1 and TRPV2 were significantly elevated [38]. Collectively, miR-429 potentially suppressed neurotrophin-3 to alleviate PNI of PDAC.…”

Section: Mir-429 Downregulation In Cancersmentioning

confidence: 88%

miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review

Guo

Liu

Sun

2020

neo

View full text Add to dashboard Cite

miR-429 is a member of miR-200 family. Accumulated evidence has indicated that miR-429 dysregulation is involved in the epithelial-mesenchymal transition (EMT), progression, development, invasion, metastasis, apoptosis and drug resistance of a variety of cancers. miR-429 might specifically function either as a tumor suppressor or promoter candidate for certain cancers depending on the particular types of tumor cells/tissues. miR-429 appears to have a tumor-suppression role in renal cell carcinoma (RCC), breast cancer (BC), gastric carcinoma (GC), glioblastoma (GBM), esophageal cancer (EC), osteosarcoma, oral squamous cell carcinoma (OSCC), cervical cancer (CC), pancreatic cancer, tongue squamous cell carcinoma (TSCC), nephroblastoma, nasopharyngeal carcinoma (NPC) and soft tissue sarcomas. On the other hand, miR-429 has a tumor-promotion role in endometrial cancer (EmCa), prostate cancer (CaP) and lung cancer (LC). However, miR-429 shows paradoxical role in colorectal cancer (CRC), hepatocellular carcinoma (HCC), bladder cancer and ovarian cancer (OC). This article summarizes the associations between miR-429 and malignant tumors as well as potential action mechanisms. miR-429 has a potential to be used in the future as a biomarker for the diagnosis, treatment and prognosis of certain cancers.

show abstract

Section: Mir-429 Downregulation In Cancersmentioning

confidence: 88%

miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review

Guo

Liu

Sun

2020

neo

View full text Add to dashboard Cite

show abstract

“…For example, miR-429 expression was downregulated in human thyroid cancer and it inhibited cell growth and promoted cell apoptosis (33). Moreover, miR-429 served as a suppressor in cervical cancer (34) and in pancreatic cancer (35). However, studies concerning miR-429 expression and its functional effect in OS are still rare and it is therefore necessary to investigate the underlying mechanisms of miR-429 in OS.…”

Section: Discussionmentioning

confidence: 99%

miR‑429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β‑catenin signaling pathway

Sun

Wang²,

Luan

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most commonly diagnosed malignant cancer of bone that occurs in adolescents and children. Mounting number of studies have indicated that miRNAs are increasingly playing fundamental roles in OS development. Thus, the biological function of miR-429 in OS progression was explored. The results of RT-qPCR revealed that miR-429 was downregulated in OS tissues and OS cell lines (MG-63, U2OS, Saos-2) while homeobox A9 (HOXA9) was markedly increased. Moreover, HOXA9 was confirmed as a direct target of miR-429 by using luciferase reporter assay. It was identified that miR-429 exhibited a suppressive effect on OS progression while HOXA9 showed the oncogenic function in OS progression by using MTT and Transwell assays. More importantly, rescue assays manifested that HOXA9 can partially overturn the suppressive effect of miR-429 on OS. Overexpression of miR-429 inhibited the activation of Wnt/β-catenin signaling pathway. In conclusion, miR-429 suppressed OS progression by targeting HOXA9 through Wnt/β-catenin pathway.

show abstract

“…The LASSO regression method was used to further determine the ncRNA signature, which identified 8 CpG sites of miRNA and 7 CpG sites of lncRNA with regression coefficients: miR-200a, miR-935, miR-124-3, miR-129-2, miR-1249, miR-4479, miR-615, miR-429, LINC00421, KB-1732A1.1, LINC00900, RP11-175E9.1, RP11-465B22.8, RP11-676J15.1, and MIR4500HG. Reports have indicated that most of the 8 miRNAs are closely related to tumorigenesis [17–21] while none of the lncRNAs have been studied. Among the 8 miRNAs, miR-200a plays a vital part in the mesenchymal-to-epithelial transition process of pancreatic cancer stem cells by altering cancer migration and invasion [22].…”

Section: Discussionmentioning

confidence: 99%

The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma

et al. 2019

View full text Add to dashboard Cite

Background Compelling lines of evidence indicate that DNA methylation of non-coding RNAs (ncRNAs) plays critical roles in various tumour progression. In addition, the differential methylation of ncRNAs can predict prognosis of patients. However, little is known about the clear relationship between DNA methylation profile of ncRNAs and the prognosis of pancreatic adenocarcinoma (PAC) patients. Methods The data of DNA methylation, RNA-seq, miRNA-seq and clinical features of PAC patients were collected from TCGA database. The DNA methylation profile was obtained using the Infinium HumanMethylation450 BeadChip array. LASSO regression was performed to construct two methylation-based classifiers. The risk score of methylation-based classifiers was calculated for each patient, and the accuracy of the classifiers in predicting overall survival (OS) was examined by ROC curve analysis. In addition, Cox regression models were utilized to assess whether clinical variables and the classifiers were independent prognostic factors for OS. The targets of miRNA and the genes co-expressed with lncRNA were identified with DIANA microT-CDS and the Multi-Experiment Matrix (MEM), respectively. Moreover, DAVID Bioinformatics Resources were applied to analyse the functional enrichment of these targets and co-expressed genes. Results A total of 4004 CpG sites of miRNA and 11,259 CpG sites of lncRNA were screened. Among these CpG sites, 8 CpG sites of miRNA and 7 CpG sites of lncRNA were found with regression coefficients. By multiplying the sum of methylation degrees of the selected CpGs with these coefficients, two methylation-based classifiers were constructed. The classifiers have shown good performance in predicting the survival rate of PAC patients at varying follow-up times. Interestingly, both of these two classifiers were predominant and independent factors for OS. Furthermore, functional enrichment analysis demonstrated that aberrantly methylated miRNAs and lncRNAs are related to calcium ion transmembrane transport and MAPK, Ras and calcium signalling pathways. Conclusion In the present study, we identified two methylation-based classifiers of ncRNA associated with OS in PAC patients through a comprehensive analysis of miRNA and lncRNA profiles. We are the first group to demonstrate a relationship between the aberrant DNA methylation of ncRNAs and the prognosis of PAC, and this relationship would contribute to individualized PAC therapy. Electronic supplementary material The online version of this article (10.1186/s12935-019-0828-8) contains supplementary material, which is available to authorized users.

show abstract

MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer

Cited by 25 publications

References 20 publications

miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review

miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review

miR‑429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β‑catenin signaling pathway

The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma

Contact Info

Product

Resources

About